Delays in Initiating Anti-Cancer Therapy for Early-Stage Breast Cancer-How Slow Can We Go?

Publication date: Jul 05, 2023

Breast cancer is the most commonly diagnosed cancer among women worldwide, and is a leading cause of cancer-related deaths. When diagnosed at an early stage, appropriate and timely treatment results in a high cure rate and better quality of life. Delays in initiating anti-cancer therapy, including surgical resection, adjuvant/neoadjuvant chemotherapy and radiation therapy are commonly encountered, even in developed health care systems. Existing comorbidities that mandate referral to other services, genetic counseling and testing that may dictate the extent and type of anti-cancer therapy and insurance coverage, are among the most commonly cited factors. However, delays can be unavoidable; for over three years, health care systems across the globe were busy dealing with the unprecedented COVID-19 pandemic. War across hot zones around the globe resulted in millions of refugees; most of them have no access to cancer care, and when/where available, there may be significant delays. Thus, cancer patients across the globe will probably continue to suffer from significant delays in diagnosis and appropriate treatment. Many retrospective reports showed significant negative impacts on different aspects of treatment outcomes and on patients’ psychosocial wellbeing and productivity. In this paper, we review the available data on the impact of delays in initiating appropriate treatment on the outcomes of patients with early-stage breast cancer.

Open Access PDF

Concepts Keywords
Chemotherapy breast cancer
Genetic COVID-19
Hot pandemic
Pandemic refugees
Refugees time to treatment
treatment delays


Type Source Name
disease MESH Cancer
disease MESH Breast Cancer
pathway KEGG Breast cancer
drug DRUGBANK Tropicamide
disease IDO quality
disease MESH COVID-19 pandemic
drug DRUGBANK Coenzyme M
disease VO Canada
disease IDO host
disease MESH chronic illnesses
drug DRUGBANK Trestolone
disease MESH death
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease IDO process
disease VO TTC
disease VO population
drug DRUGBANK Acetylcysteine
disease VO Hormone
disease VO USA
disease IDO country
drug DRUGBANK Methionine
disease MESH triple negative breast cancer
disease MESH metastasis
disease VO age
disease MESH complications
disease MESH premature mortality
disease MESH morbidity
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
drug DRUGBANK Olaparib
disease MESH carcinoma
disease VO time
disease MESH Thyroid Cancer
pathway KEGG Thyroid cancer
drug DRUGBANK Carboxyamidotriazole
disease MESH Neck Cancer

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *